# Pneumococcal Conjugate Vaccines

| Vaccine Description | • Brand: VAXNEUVANCE™ (PCV15)  
|                     | • Brand: Prevnar 20™ (PCV20)  
|                     | • Inactivated protein-conjugated vaccines  
|                     | • Contain diphtheria protein and aluminum phosphate  
|                     | • See package inserts for more information and full lists of vaccine components |
| Dose & Route        | • Dose: 0.5 mL  
|                     | • Route: IM |
| Indications         | • All persons 2 – 59 months of age  
|                     | • Persons 6 – 18 years of age with certain risk factors:  
|                     |   ° Cerebrospinal fluid (CSF) leak  
|                     |   ° Chronic heart disease (especially cyanotic congenital heart disease and cardiac failure)  
|                     |   ° Chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome, which are included in immunocompromising conditions)  
|                     |   ° Chronic liver disease  
|                     |   ° Chronic lung disease (including moderate persistent or severe persistent asthma)  
|                     |   ° Cochlear implant  
|                     |   ° Diabetes mellitus  
|                     |   ° Immunocompromising conditions (e.g., on maintenance dialysis or with nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; and sickle cell disease or other hemoglobinopathies). |
Pneumococcal Conjugate Vaccines
(Continued)

| Administration Schedules | • VAXNEUVANCE™ (PCV15)  
|                          |   ° Age 2 - 59 months: four routine doses at ages 2, 4, 6, and 12 - 15 months  
|                          |   ° An additional dose may be indicated at ages 6 - 18 years.  
|                          | • Prevnar 20™ (PCV20)  
|                          |   ° Age 2 - 59 months: four routine doses at ages 2, 4, 6, and 12 - 15 months  
|                          |   ° Doses may be indicated at ages 2 - 18 years for persons who only received PCV13 or PCV15.  
|                          | • See Pneumococcal Vaccine Schedule tables on the following pages for specific dosing and intervals. |
| Contraindications        | • Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine, to any vaccine containing diphtheria toxoid, or to a vaccine component (including yeast) |
| Precautions              | • Moderate or severe acute illness with or without fever. |
| Special Considerations   | • Pregnancy: provider may consider giving if increased risk for infection or poor outcome from infection.  
|                          | • For individuals with anatomic or functional asplenia and/or HIV: PCV vaccines and Menactra (MenACYW-D) should not be given concomitantly. Administer Menactra ≥ 4 weeks after completion of all PCV doses. |

VIS: [http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.html](http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.html)
MMWR: [https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm](https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm)
Standing orders: [www.health.mil/standingorders](http://www.health.mil/standingorders)
Additional education may be found at [www.health.mil/pneumococcal](http://www.health.mil/pneumococcal)
### Pneumococcal Polysaccharide Vaccine

| Vaccine Description | • **Brand:** PNEUMOVAX 23® (PPSV23)  
|                     | • Inactivated bacterial polysaccharide vaccine  
|                     | • Contains phenol  
|                     | • See package insert for more information and a full list of vaccine components |
| Dose & Route        | • Dose: 0.5 mL  
|                     | • Route: IM or SC |
| Indications         | • Persons 2 – 18 years of age with certain risk factors (see Pneumococcal Conjugate Vaccines – Pediatric above) who previously received PCV13 or PCV15.  
|                     | • Not indicated for individuals who previously received PCV20. |
| Administration Schedule | • One or two doses after receipt of PCV13 or PCV15  
|                       | ° When PCV20 is used, no subsequent PPSV23 is recommended.  
|                       | • See Pneumococcal Vaccine Schedule table on the following page for specific dosing and intervals. |
| Contraindications   | • Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine or to a vaccine component. |
| Precautions         | • Moderate or severe acute illness with or without fever.  
|                     | • Persons with severely compromised cardiovascular or pulmonary function in whom a systemic reaction would pose a significant risk. |
| Special Considerations | • Pregnancy: provider may consider giving if increased risk for infection or poor outcomes from infection. |

VIS: [http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html](http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html)  
MMWR: [https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm](https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm)  
Standing orders: [www.health.mil/standingorders](http://www.health.mil/standingorders)  
Additional education may be found at [www.health.mil/pneumococcal](http://www.health.mil/pneumococcal)
Pneumococcal Vaccine Schedule (Pediatric)

Age 2 – 59 months (all individuals)

Routine schedule:

- PCV15 or PCV20
- PCV15 or PCV20
- PCV15 or PCV20
- PCV15 or PCV20

Age 2 – 18 years with any risk condition* and completed all recommended routine PCV doses before age 6 years:

a. Recommended routine PCV doses included ≥ 1 dose PCV20:

   - No additional doses of any pneumococcal vaccine indicated until age ≥ 65 years

b. Recommended routine PCV doses included PCV13 or PCV15 (no PCV20):

   - Last recommended PCV13 or PCV15
   - 8 weeks
   - PCV20 OR PPSV23

   - Additional doses for immunocompromising conditions:
     - Asplenia or splenic dysfunction
     - Chronic renal failure
     - Generalized malignancy
     - HIV infection
     - Hodgkin disease
     - Idiopathic immune suppression
     - Leukemia
     - Lymphoma
     - Multiple myeloma
     - Nephrotic syndrome, or on maintenance dialysis
     - SCD or other hematopoietic syndromes
     - Solid organ transplant

   - 5 years
   - PCV20 OR PPSV23

Age 6 – 18 years with any risk condition* and have not received PCV13, PCV15, or PCV20:

- PCV20
- No additional doses of any pneumococcal vaccine indicated until age ≥ 65 years
- OR
- PCV15
- 8 weeks
- PPSV23

If PCV15 and PPSV23 are used instead of PCV20 for children with an immunocompromising condition*, either PCV20 or a second PPSV23 dose is recommended 5 years later (see additional dose after PPSV23 in section b above).

- Complete all recommended PCV doses before giving PPSV23
- No more than two doses of PPSV23 recommended before age 65 years